According to a press release from Praxis Precision Medicines, the results from its PRAX-114 Phase 2/3 Monotherapy Aria Study were disappointing. The company notes it didn’t meet its primary endpoint of statistical improvement on the 17-item Hamilton Depression Rating Scale.
Marcio Souza, president and CEO of Praxis Precision Medicines, said the following about the clinical trial results:
“We are surprised and disappointed in the Aria Study results … PRAX-114 was well-tolerated in the Aria Study, yet the effect did not deliver to meet the needs of patients.”
Praxis Precision Medicines notes these results mean major changes for the company. That includes laying off staff and realigning its business. This will have it focusing on PRAX-944 and PRAX-562 instead.
PRAX stock is seeing heavy trading today alongside the clinical trial news. This has more than 11 million shares of the stock changing hands as of this writing. That’s well above its daily average trading volume of about 329,000 shares.
PRAX stock is down 65.2% as of Monday morning.
There’s more stock market news worth diving into below!
We’ve got all the hottest stock news traders need to know about for Monday! That includes why Chinese stocks are rising, what has Nio (NYSE:NIO) gaining as well as what to expect from WWDC 2022. You can catch up on this news at the links below!
More Monday Stock Market News
- BABA, PDD, BIDU, DIDI: Why Are Chinese Stocks Up Today?
- NIO Stock Is up 8% As Nio Looks Set to Achieve Breakeven in 2024
- WWDC 2022: 11 Things to Know About This Year’s Apple Developers Event
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.